title: End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.
authors.affiliation: Virginia Commonwealth University School of Medicine, Richmond, Virginia. Electronic address: arun.sanyal@vcuhealth.org.
authors.forename: Arun J
authors.initials: AJ
authors.lastname: Sanyal
authors.affiliation: Saint Louis University School of Medicine, St. Louis, Missouri.
authors.forename: Brent A
authors.initials: BA
authors.lastname: Neuschwander-Tetri
authors.affiliation: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
authors.forename: James
authors.initials: J
authors.lastname: Tonascia
mesh_terms: D001707:Biopsy, Needle; D002908:Chronic Disease; D055808:Drug Discovery / Q000379:methods*; D015507:Drugs, Investigational / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D020380:Needs Assessment; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis* / Q000188:drug therapy*; D012720:Severity of Illness Index; D014481:United States
chemical_list: D015507:Drugs, Investigational